Journal of Cancer Research and Clinical Oncology

, Volume 135, Issue 10, pp 1429–1435

Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy

  • Stefan Wilop
  • Sabine von Hobe
  • Martina Crysandt
  • Albert Esser
  • Rainhardt Osieka
  • Edgar Jost
Original Paper

DOI: 10.1007/s00432-009-0587-3

Cite this article as:
Wilop, S., von Hobe, S., Crysandt, M. et al. J Cancer Res Clin Oncol (2009) 135: 1429. doi:10.1007/s00432-009-0587-3

Abstract

Purpose

The renin-angiotensin system plays a crucial role in maintaining vascular homeostasis. Stimulation of angiotensin II type 1 receptors (AT1R) acts proangiogenically by increasing levels of vascular endothelial growth factor (VEGF). Consequently, cell culture experiments and animal studies have shown antiproliferative effects of AT1R blockers (ARB) and angiotensin I converting enzyme inhibitors (ACEI) in several malignancies. Until now, very limited clinical data for this antiangiogenic effect exists for combinations with antineoplastic chemotherapy.

Methods

A total of 287 patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy were retrospectively analysed regarding long-term medication with ACEI and ARB as well as histological type, stage, performance status, gender, age, dose-intensity of chemotherapy and survival.

Results

Patients receiving either ACEI or ARB had a 3.1 months longer median survival than non-recipients (11.7 vs. 8.6 months, HR 0.56, P = 0.03). This survival advantage could not be attributed to other established risk-factors or dose intensity of chemotherapy.

Conclusions

Addition of ACEI or ARB to platinum-based first-line chemotherapy may contribute to prolonged survival in patients with advanced lung cancer.

Keywords

Angiotensin converting enzyme inhibitors Angiotensin II receptor blockers Chemotherapy Antiangiogenesis Non-small-cell lung cancer 

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Stefan Wilop
    • 1
  • Sabine von Hobe
    • 2
  • Martina Crysandt
    • 1
  • Albert Esser
    • 1
  • Rainhardt Osieka
    • 1
  • Edgar Jost
    • 1
  1. 1.Medizinische Klinik IVUniversitaetsklinikum Aachen, RWTH AachenAachenGermany
  2. 2.ApothekencenterUniversitaetsklinikum Aachen, RWTH AachenAachenGermany

Personalised recommendations